ARKG vs XBI
ARK Genomic Revolution ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.75% for ARKG.
- • XBI pays a higher dividend yield (0.36%).
Side-by-side metrics
| Metric | ARKG | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $1.73B | $10.73B |
YTD return | 44.53% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.38 | 1.10 |
P/E ratio | — | — |
Last price | $43.17 | $164.01 |
Inception | — | — |
Issuer | ARK | State Street |
ARKG top holdings
| TWST | Twist Bioscience Corp | 9.15% |
| TEM | Tempus AI Inc Class A common stock | 7.64% |
| ABSI | Absci Corp | 7.01% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 7.00% |
| CRSP | CRISPR Therapeutics AG | 6.56% |
| PSNL | Personalis Inc | 6.19% |
| BEAM | Beam Therapeutics Inc | 4.34% |
| GH | Guardant Health Inc | 4.28% |
| NTRA | Natera Inc | 4.11% |
| ILMN | Illumina Inc | 3.98% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 9.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.